France has scaled back a planned round of price reductions across generic medicine groups after discussions with pharmacy representatives highlighted supply pressures, limited competition and the commercial sustainability of some mature products.
APMnews reported on 1 July that the Economic Committee for Health Products (Comité économique des produits de santé, CEPS) was preparing a package of price reductions expected to generate €43.9 million of savings for National Health Insurance in 2027. The proposals covered a series of established generic groups and were due to be discussed through the Generic Medicines Monitoring Committee (Comité de suivi des génériques, CSG).
Following the CSG meeting on 23 July, the Union of Community Pharmacists (Union des syndicats de pharmaciens d’officine, USPO) reported that nine of the 12 groups initially targeted had been removed from the programme. Expected savings consequently fell to €24.2 million, avoiding close to €20 million of proposed price reductions.
USPO said the changes followed review of factors including current supply difficulties, the number of manufacturers remaining in individual markets, substitution rates and the potential effect of further price reductions on domestic production. Separate reporting based on comments from the Federation of Pharmaceutical Unions of France (Fédération des syndicats pharmaceutiques de France, FSPF) also put the revised savings at around €24 million and indicated that the remaining reductions were expected to apply from 1 January 2027.
The episode illustrates the increasingly narrow margin available when France seeks further savings from some off-patent medicine markets. Generic competition remains an important source of expenditure reduction, but repeated price erosion can become harder to sustain where competition is already weak or supply is fragile.
This balance is becoming more prominent in French medicines policy. Recent official reports have called for greater use of direct price reductions to control expenditure, while wider supply-policy discussions have emphasised the need to preserve sufficiently attractive market conditions to maintain multiple suppliers.
The July outcome therefore suggests a more selective approach to generic price reductions, with expected savings moderated where additional cuts could weaken competition or increase supply risk. CEPS has not published a consolidated account of the final July package, but the revised figures and scope have been consistently reported through specialist and stakeholder sources.
Source: APMnews
Link: Le CEPS vise 44 millions d'euros d'économies sur les prix de dix groupes génériques (CEPS targets €44 million in savings from prices in ten generic groups)
Date: 1 July 2026
Source: Union of Community Pharmacists
Link: L’USPO obtient gain de cause auprès du CEPS : près de 20 millions d’euros de baisses de prix évitées (USPO succeeds with CEPS: nearly €20 million in price reductions avoided)
Date: 28 July 2026
Source: AFP/Boursorama
Link: Sécu : 24 millions d'euros d'économies générées en 2027 grâce à des baisses de prix de médicaments génériques(Social Security: €24 million in savings to be generated in 2027 through generic medicine price reductions)
Date: 29 July 2026
